Among individuals with type 2 diabetes, country-standardized cognitive score may predict risk for cardiovascular events<\/p>\n<\/h3>\n
<\/b><\/p>\n
<\/b><\/p>\n
TUESDAY, April 26, 2022 (HealthDay News) — For individuals with type 2 diabetes, subjective cognitive impairment (SCI) is associated with cardiovascular events, according to a study published online April 21 in the Journal of Clinical Endocrinology & Metabolism<\/em>.<\/p>\n Tali Cukierman-Yaffe, M.D., from Sheba Medical Center in Ramat-Gan, Israel, and colleagues examined whether low cognitive scores are risk factors for cardiovascular outcomes in 8,772 participants with type 2 diabetes in the Researching Cardiovascular Events with a Weekly Incretin in Diabetes trial who completed both the Montreal Cognitive Assessment (MoCA) and Digit Substitution Test (DSST) at baseline. A baseline score on either the MoCA or DSST \u00e2\u0089\u00a51.5 standard deviations below either score’s country-specific mean (SCI-GM) was used to identify participants with baseline SCI, and the associations with incident major adverse cardiovascular events (MACE) and either stroke or death were examined.<\/p>\n The researchers found that the 10.3 percent of participants with baseline SCI had a higher incidence of MACE and stroke or death compared with the 89.7 percent of participants who were unaffected (unadjusted hazard ratios, 1.34 and 1.60, respectively).The associations were stronger for SCI-GM with MACE and stroke or death (unadjusted hazard ratios, 1.61 and 1.85, respectively). These relationships remained significant for SCI-GM, but not for SCI, in models that adjusted for up to 10 SCI risk factors.<\/strong><\/p>\n “Although the explanation for this remains unclear, proven heart medications should be offered to these patients to reduce their future risk of a heart attack or stroke,” a coauthor said in a statement.<\/p>\n Several authors disclosed financial ties to pharmaceutical companies, including Eli Lilly, which funded the Researching Cardiovascular Events with a Weekly Incretin in Diabetes trial.<\/p>\n Abstract\/Full Text (subscription or payment may be required)<\/a><\/p>\n <\/i><\/p>\n